Cizzle Biotechnology Holdings Plc engages in developing a blood test for the early detection of various forms of lung cancer. It develops CIZ1B protein gene and its potential as a diagnostic biomarker for detection and management of lung cancer. The company's Ciz1 promotes DNA replication and its organization and control. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc was incorporated in 2004 and is headquartered in London, the United Kingdom.